Archford Capital Strategies’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Archford Capital Strategies’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-6,426	Closed	-$808K	–	316
2021 Q3	$808K	Buy	6,426 +235	+4%	+$30.3K	0.19%	136
2021 Q2	$838K	Buy	6,191 +79	+1%	+$10.4K	0.21%	127
2021 Q1	$816K	Buy	6,112 +1,057	+21%	+$158K	0.22%	126
2020 Q4	$756K	Buy	5,055 +1,109	+28%	+$142K	0.17%	160
2020 Q3	$440K	Buy	3,946 +732	+23%	+$82.1K	0.12%	184
2020 Q2	$360K	Buy	3,214 +601	+23%	+$59.2K	0.11%	187
2020 Q1	$202K	Buy	+2,613	New	+$231K	0.08%	207
2019 Q3	–	Sell	-650	Closed	-$57K	–	526
2019 Q2	$57K	Hold	650	–	–	0.02%	270
2019 Q1	$59K	Hold	650	–	–	0.02%	269
2018 Q4	$47K	Hold	650	–	–	0.02%	269
2018 Q3	$62K	Hold	650	–	–	0.02%	280
2018 Q2	$62K	Hold	650	–	–	0.02%	284
2018 Q1	$55K	Buy	+650	New	+$59.3K	0.02%	201
2017 Q2	–	Sell	-650	Closed	-$45K	–	633
2017 Q1	$45K	Hold	650	–	–	0.02%	293
2016 Q4	$38K	Hold	650	–	–	0.02%	275
2016 Q3	$43K	Hold	650	–	–	0.02%	273
2016 Q2	$35K	Buy	+650	New	+$35.6K	0.02%	285

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Archford Capital Strategies's XBI Position: Q4 2021 in Review

Archford Capital Strategies sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2021, closing a stake of 6,426 shares — an estimated $808K sold.

Archford Capital Strategies first reported a position in XBI in Q2 2016 and held it in 17 quarters. The position peaked at $838K in Q2 2021. 702 funds tracked by Wall St. Rank hold XBI as of Q4 2021.

Archford Capital Strategies reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2021 after selling out during the quarter.
Archford Capital Strategies sold 6,426 State Street SPDR S&P Biotech ETF shares in Q4 2021, an estimated $808K.
Archford Capital Strategies first reported a position in State Street SPDR S&P Biotech ETF in Q2 2016 and held it in 17 quarters.
Archford Capital Strategies's State Street SPDR S&P Biotech ETF position peaked at $838K in Q2 2021.
702 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2021.

Based on Archford Capital Strategies's 13F filing for Q4 2021, filed 20 Jan 2022.